Esperion Therapeutics | Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.29B 3.9B 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Alterity Therapeutics Limited AUD 4.38M 849.82K 2023-06
Amarin USD 182.23M 3.71M 2025-09
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Cipla INR 62.97B 8.13B 2025-09
CSL USD 4.61B 207M 2025-12
Cytokinetics USD 202.45M 60.31M 2025-12
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 359.03M 60.24M 2025-09
Geron USD 113.82M 26.11M 2025-12
Grifols EUR 2.53B 182.67M 2025-09
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 89.71M 168.89M 2025-09
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Merck USD 28.63B 2.59B 2025-09
Minerva Neurosciences USD 2.67M 143K 2025-09
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12


Esperion Therapeutics Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.